Patricia Diez

Patricia Diez

Auto-generated profile, based on publicly available information

Patricia Diez

National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, London, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
DCDavid J. Cutter
David J. Cutter
JRJohanna Ramroth
Johanna Ramroth
PDPatricia Diez
Patricia Diez
ABAndy Buckle
Andy Buckle
GNGeorgios Ntentas
Georgios Ntentas
TITimothy Illidge
Timothy Illidge
PURPOSE: The contemporary management of early-stage Hodgkin lymphoma (ES-HL) involves balancing the risk of late adverse effects of radiotherapy against the increased risk of relapse if radiotherapy is omitted. This study provides information on the risk of radiation-related cardiovascular disease to help personalize the delivery of radiotherapy in ES-HL. METHODS: We predicted 30-year absolute cardiovascular risk from chemotherapy and involved field radiotherapy in patients who were positron emission tomography (PET)–negative following three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy within a UK randomized trial of PET-directed therapy for ES-HL. Cardiac and carotid radiation doses and chemotherapy exposure were combined with established dose-response relationships and population-based mortality and incidence rates. RESULTS: Average mean heart dose was 4.0 Gy (range 0.1-24.0 Gy) and average bilateral common carotid artery dose was 21.5 Gy (range 0.6-38.1 Gy), based on individualized cardiovascular dosimetry for 144 PET-negative patients receiving involved field radiotherapy. The average predicted 30-year radiation-related absolute excess overall cardiovascular mortality was 0.56% (range 0.01%-6.79%; < 0.5% in 67% of patients and > 1% in 15%), whereas average predicted 30-year excess incidence was 6.24% (range 0.31%-31.09%; < 5% in 58% of patients and > 10% in 24%). For cardiac disease, the average predicted 30-year radiation-related absolute excess mortality was 0.42% (0.79% with mediastinal involvement and 0.05% without) and for stroke, it was 0.14%. CONCLUSION: Predicted excess cardiovascular risk is small for most patients, so radiotherapy may provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced radiotherapy techniques to reduce doses or to omit radiotherapy and accept the increased relapse risk. Individual assessment of cardiovascular and other risks before treatment would allow personalized decision making about radiotherapy in ES-HL.

1 September 2016 in Practical Radiation Oncology
Verified
Journal Article
Closed access
GEGemma Eminowicz
Gemma Eminowicz
MHMargaret Hall-Craggs
Margaret Hall-Craggs
PDPatricia Diez
Patricia Diez
MMMary McCormack
Mary McCormack

1 March 2023 in British Journal of Radiology
Verified
Journal Article
Open access
SMSarah Misson-Yates
Sarah Misson-Yates
RCRissa Cunningham
Rissa Cunningham
RGRegina Gonzalez
Regina Gonzalez
PDPatricia Diez
Patricia Diez
CCCatharine H Clark
Catharine H Clark
The use of volumetric arc therapy and inverse planning has been in routine use in radiotherapy for two decades. However, use in total body irradiation (TBI) has been more recent and few guidelines exist as to how to plan or verify. This has led to heterogeneous approaches. The goal of this review is to provide an overview of current advanced planning and dosimetry verification protocols used in optimised conformal TBI as a basis for investigating the need for greater standardisation in TBI.

1 December 2014 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDPatricia Díez
Patricia Díez
VMVinod Mullassery
Vinod Mullassery
PDPittaya Dankulchai
Pittaya Dankulchai
POPeter Ostler
Peter Ostler
RHRobert Hughes
Robert Hughes
PHPeter J. Hoskin
Peter J. Hoskin

9 November 2017 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
PDP Díez
P Díez
EAE G A Aird
E G A Aird
TST Sander
T Sander
CGC A Gouldstone
C A Gouldstone
PSP H G Sharpe
P H G Sharpe
APA L Palmer
A L Palmer
A UK multicentre audit to evaluate HDR and PDR brachytherapy has been performed using alanine absolute dosimetry. This is the first national UK audit performing an absolute dose measurement at a clinically relevant distance (20 mm) from the source. It was performed in both INTERLACE (a phase III multicentre trial in cervical cancer) and non-INTERLACE brachytherapy centres treating gynaecological tumours. Forty-seven UK centres (including the National Physical Laboratory) were visited. A simulated line source was generated within each centre’s treatment planning system and dwell times calculated to deliver 10 Gy at 20 mm from the midpoint of the central dwell (representative of Point A of the Manchester system). The line source was delivered in a water-equivalent plastic phantom (Barts Solid Water) encased in blocks of PMMA (polymethyl methacrylate) and charge measured with an ion chamber at 3 positions (120° apart, 20 mm from the source). Absorbed dose was then measured with alanine at the same positions and averaged to reduce source positional uncertainties. Charge was also measured at 50 mm from the source (representative of Point B of the Manchester system). Source types included 46 HDR and PDR 192 Ir sources, (7 Flexisource, 24 mHDR-v2, 12 GammaMed HDR Plus, 2 GammaMed PDR Plus, 1 VS2000) and 1 HDR 60 Co source, (Co0.A86). Alanine measurements when compared to the centres’ calculated dose showed a mean difference (±SD) of +1.1% (±1.4%) at 20 mm. Differences were also observed between source types and dose calculation algorithm. Ion chamber measurements demonstrated significant discrepancies between the three holes mainly due to positional variation of the source within the catheter (0.4%–4.9% maximum difference between two holes). This comprehensive audit of absolute dose to water from a simulated line source showed all centres could deliver the prescribed dose to within 5% maximum difference between measurement and calculation.

19 December 2025 in Clinical Oncology
Verified
Journal Article
Closed access
KMK. Mackay
K. Mackay
KBK. Banfill
K. Banfill
DBD. Bernstein
D. Bernstein
JDJ. Daniel
J. Daniel
PDP. Diez
P. Diez
ATA. Taylor
A. Taylor